Italia markets closed

Easywell Biomedicals, Inc. (1799.TWO)

Taipei Exchange - Taipei Exchange Prezzo differito. Valuta in TWD.
Aggiungi a watchlist
130,00+11,50 (+9,70%)
Alla chiusura: 01:30PM CST

Easywell Biomedicals, Inc.

No.10, Yanfa 2nd Road
Hsinchu Science Park
Hsinchu City 30076
Taiwan
886 3 666 9596
https://www.easywellbio.com

Settore/iHealthcare
SettoreMedical Devices
Impiegati a tempo pieno

Figure dirigenziali chiave

NomeTitoloRetribuzioneEsercitateAnno di nascita
Mr. James Lee Ph.D.PresidentN/DN/DN/D
Dr. Yu-Hsing Tu Ph.D.Chief Science OfficerN/DN/DN/D
Dr. She Bin-Ru Ph.D.Chief Technical Officer of Regenerative Medicine DivisionN/DN/DN/D
Gli importi risalgono al giorno e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in TWD.

Descrizione

Easywell Biomedicals, Inc. develops, manufactures, and sells active pharmaceutical ingredients and over-the-counter drug products in the United States and Asia. It develops TLX-001, an anti-cough medicine; TLX-005, an anti-urinary incontinence medicine; TLX-006 for treatment of breast cancer in PMS women; TLX-007 and TLX-004, an anti-depressant; TLX-008 for prevention of pneumocystis pneumonia; TLX-012 for treatment of epilepsy; TLX-017 for treatment of chronic angina; and TLX-011 for treatment of inflammatory lesions of rosacea. The company also develops TWB-201 for Parkinson patch; TLX-501, an urinary medicine; and TLX-502, a pneumonia medicine. In addition, it provides medical devices. The company was formerly known as Actherm Inc. and changed its name to Easywell Biomedicals, Inc. in July 2015. Easywell Biomedicals, Inc. was incorporated in 1998 and is headquartered in Hsinchu City, Taiwan.

Governance aziendale

L'ISS Governance QualityScore di Easywell Biomedicals, Inc. al N/D è N/D. I criteri di valutazione fondamentali sono revisione: N/D; Consiglio di Amministrazione: N/D; diritti degli azionisti: N/D; retribuzione: N/D.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.